Previously, CMH, as we show here (Figure 3), was shown to restore sensitivity to death receptor ligands in a cell-based high-throughput screening using the Fas- and TRAIL-resistant prostate cancer cell line [36,37]. Here, FAS is linked to prostate cancer.